Homozygous familial hypercholesterolemia (HoFH) is a genetic condition that is associated with very high levels of LDL-c from birth. Prof. Ray shows how outcomes can be improved by earlier diagnosis and use of multiple lipid-lowering treatments.

The National Institute for Health and Care Excellence (NICE) has published a final draft guidance which recommends use of icosapent ethyl in adults with CVD, statin-controlled LDL-c levels and elevated triglycerides.

GLP-1RAs may result in beneficial effects on renal outcomes, as shown by analyses of secondary endpoints in large trials. What are the potential mechanisms leading to CVD and CKD risk reduction?

Historically, HDL-c is regarded as the ‘good’ cholesterol. But does this also apply to patients with coronary artery disease and very high HDL-c levels? In a recent analysis, this was examined using data from 2 large cohorts.

EAS 2022 A study found that Lp(a) is not associated with VTE and the increased risk of MI caused by high Lp(a) levels is unlikely to be decreased by antiplatelet or antithrombin therapy.

EAS 2022 An ASO targeting ANGPTL3 mRNA, significantly reduced VLDL and remnant cholesterol, but had side effects at higher doses. What could be next steps in this research area?

EAS 2022 Data on characteristics of FH in children are critical to inform contemporary approaches to identify children/adolescents with FH worldwide.

Bempedoic acid has been approved by the FDA in 2020, but what is the potential place of bempedoic acid in the arsenal of lipid-lowering therapies? With question to test your knowledge.

Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.

What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.

The combination of high Lp(a) levels and high BMI conferred a 3.5-fold risk of CAVD compared with both risk factors in the bottom 50%. Absolute 10-year risk of CAVD was higher in men than in women and increased with higher age, Lp(a) and BMI.

Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in patients who are already being treated with statins.